Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze

Karyopharm Therapeutics INC ((KPTI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Karyopharm Therapeutics struck a cautious tone on its earnings call, balancing excitement over looming Phase III data with clear financial strain. Management highlighted potentially transformative readouts in myelofibrosis and endometrial cancer, yet acknowledged a tight cash runway, sizeable GAAP losses and higher interest costs that leave little room for clinical or financing missteps.

Upcoming Pivotal Phase III Readouts

Top line data from the Phase III SENTRY trial in myelofibrosis are expected in March 2026, with EXPORT EC042 in endometrial cancer to follow by mid 2026. Executives framed both studies as potential practice changing events and the primary near term value drivers that could reshape the company’s commercial profile if results are positive.

Compelling Early Clinical Signals

Early combination data showed an SVR35 response rate near 79%, more than double historical ruxolitinib benchmarks around 33%. Investigators also reported larger symptom score improvements and early blinded safety from SENTRY suggesting lower grade 3 plus anemia and manageable non hematologic toxicities that could support future uptake.

Commercial Performance and 2026 Revenue Guidance

U.S. XPOVIO net product revenue grew 9.6% year over year in Q4 2025 to $32.1 million and 1.9% for the full year to $114.9 million. Total revenue reached $34.1 million in Q4 and $146.1 million for 2025, while management guided 2026 total revenue to $130 million to $150 million with U.S. XPOVIO contributing $115 million to $130 million.

Disciplined Operating Cost Reductions

Karyopharm continued to trim spending, with research and development expense down 17% in Q4 and 12% for 2025 to $27.7 million and $125.6 million respectively. Selling, general and administrative costs fell 16% in the quarter and 9% for the year to $22.8 million and $105.2 million, underscoring a pivot toward late stage programs and leaner operations.

Large Myelofibrosis Opportunity and Commercial Readiness

Management spotlighted a roughly 20,000 patient prevalent U.S. myelofibrosis population with about 6,000 new cases annually, targeting some 4,000 newly diagnosed intermediate to high risk patients. Market research suggests strong physician interest in combination regimens and the company pegs peak U.S. revenue potential near $1 billion if SENTRY succeeds.

Dose Optimization and Tolerability Strategy

The selinexor regimen in myelofibrosis has been refined to 60 milligrams weekly, which showed higher exposure and efficacy versus 40 milligrams in Phase I testing. Karyopharm also stresses mandatory dual antiemetic use early on and lower dosing than in multiple myeloma, aiming to improve tolerability and expand real world adoption.

Limited Cash Runway and Liquidity Pressure

Year end cash, cash equivalents, restricted cash and investments fell to $64.1 million from $109.1 million a year earlier, reflecting ongoing burn. Management believes current liquidity plus projected revenues will fund operations only into the second quarter of 2026, effectively tying the balance sheet to the timing and outcome of pivotal readouts.

Large GAAP Net Losses and Negative EPS

The company reported a GAAP net loss of $102.2 million in Q4 2025 and $196.0 million for the full year, translating to losses of $5.71 and $17.93 per share. Executives emphasized that much of the annual deficit stems from noncash, below the line items, but the headline figures still reflect a business far from profitability.

Higher Interest Expense and Debt Costs

Interest expense surged to $12.6 million in Q4 and $45.8 million for 2025 following debt refinancing at higher balances and rates. Karyopharm also booked a $62.4 million loss on extinguishment of debt in 2025, a sharp reversal from a $44.7 million gain in 2024 that exacerbated reported nonoperational losses.

Gross-to-Net Pressures and Revenue Headwinds

XPOVIO gross to net deductions reached 26.9% in Q4 and 31.2% for 2025, limiting net revenue growth despite solid demand trends. Overall U.S. XPOVIO sales rose just 1.9% for the year and a $15 million research reimbursement from a partner that boosted 2025 results will not repeat, creating a tougher comparison for future partner revenue.

Reliance on Binary Clinical Readouts

Karyopharm’s valuation and regulatory roadmap now hinge heavily on successful SENTRY and EXPORT EC042 outcomes. Management acknowledged that negative or inconclusive data would have outsized implications for operations and financing options given the compressed cash runway and the pivotal status of these programs.

Non-Operational Volatility in Reported Results

Other income swung to a $10.0 million expense in Q4 2025 from $10.1 million of income a year earlier, while full year other income dropped to just $0.2 million from $28.4 million. The moves largely reflect fair value swings in embedded derivatives and warrants, adding further noncash volatility to earnings per share and complicating trend analysis.

Forward-Looking Guidance and Outlook

For 2026, Karyopharm forecast total revenue of $130 million to $150 million, with U.S. XPOVIO contributing $115 million to $130 million and the remainder from partners. The company expects combined R&D and SG&A of $230 million to $245 million, and reiterated that cash plus projected revenue should fund operations into the second quarter of 2026, keeping investors focused on upcoming trial catalysts and potential financing moves.

Karyopharm’s earnings call painted a company on a knife edge, with significant scientific and commercial upside offset by real balance sheet risk. Investors will likely treat the stock as a high beta clinical catalyst play, where the pending Phase III data in 2026 and the ability to navigate the funding gap will determine whether today’s constraints give way to a stronger long term franchise.